31 results about "Therapy HIV" patented technology

The invention belongs to the technical field of medicines, and particularly relates to pyrrolo [2, 3-d] pyrimidine compounds of aryl fragments and piperidine fragments as well as a preparation method and application of the pyrrolo [2, 3-d] pyrimidine compounds. The pyrrolo [2, 3-d] pyrimidine compound containing the aryl fragment and the piperidine fragment is an HIV-1 reverse transcriptase inhibitor, and the pyrrolo [2, 3-d] pyrimidine compound further comprises pharmaceutical salt, hydrate and solvate of the pyrrolo [2, 3-d] pyrimidine compound, polycrystal or eutectic of the pyrrolo [2, 3-d] pyrimidine compound, and precursors and derivatives with the same biological functions of the pyrrolo [2, 3-d] pyrimidine compound. The invention also relates to a preparation method of the compound and application of a composition containing one or more of the compounds in related medicines for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

The invention relates to the technical field of biological medicines, in particular to an injection for treating AIDS and a preparation method thereof. The extraction method of the sulfate algae polysaccharide comprises the following steps: mixing seaweed meal, cellulase and water, carrying out enzymolysis, and extracting for 10-12 hours to obtain an extract; filtering, adding magnesium chloride hexahydrate into filtrate, standing for 20-30 minutes, centrifuging, taking supernatant, removing impurities, adding absolute ethyl alcohol until the final concentration is 55-65%, and precipitating polysaccharide; and purifying the precipitated crude polysaccharide, and freeze-drying to obtain the sulfate algae polysaccharide. The purity of the sulfate algae polysaccharide is greater than or equal to 95%, and the sulfate algae polysaccharide is cooperated with lentinan to obtain a safe and stable injection with an excellent treatment effect on AIDS (Acquired Immune Deficiency Syndrome). And a new scheme is provided for treatment of AIDS.

The present invention relates to the technical field of drug for treatment of AIDS. Disclosed are a polycyclic carbamoyl pyridone derivative, a preparation method therefor, and pharmaceutical composition thereof. The derivative comprises the compound represented by formula (I)-1 or formula (I)-2, or an isomer, pharmaceutically acceptable salt, hydrate or solvate thereof. At least one group of functional groups in (1)-(3) below and a ring A form a spirolcycle or spiroheterocycle: (1) R1 and R2; (2) R3 and R4; (3) R5 and R6; the polycyclic carbamoyl pyridone derivative can selectively inhibit the activity of HIV integrase, and thus can be used for preventing and treating AIDS.

The invention discloses an application of a PHD3 inhibitor in prevention and treatment of AIDS (acquired immune deficiency syndrome). Through multidisciplinary research means of immunology, biochemistry and the like, the situation that virus antisense protein ASP inhibits generation of I-type IFN in the HIV-1 infection process is analyzed, immune escape is achieved, and a latent infection mechanism is established. In the aspect of mechanism, the ASP can play the inhibiting role after transcriptional expression into protein in a body cell through post-translational modification, the 47-site proline of the ASP can be helped to realize the capability of inhibiting the immune response of the body after hydroxylation modification, and the post-translational modification is realized by depending on proline hydroxylase 3 (PHD3) of a host. On the basis of mechanism research, it is found that a PHD3 inhibitor Molidustat counteracts hydroxylation of PHD3 to ASP, so that immune escape of HIV-1 is blocked, infection is antagonized, and good development prospects of AIDS treatment and prevention drugs are shown.

The present invention provides a crystalline form of an HIV integrase inhibitor molecule. Specifically, the invention provides a free-state crystal form, a basic salt crystal form or an acid salt crystal form of a compound as shown in a formula I. The crystal form provided by the invention can be used for preventing and / or treating related diseases of HIV infection and selectively inhibiting the activity of HIV integrase. # imgabs0 #

The invention relates to an application of tanshinone I in preparation of a medicine for treating AIDS (Acquired Immune Deficiency Syndrome), and a tanshinone I compound is used for preparing the medicine for treating the AIDS and is applied to treatment of the AIDS. The Tanshinone I compound can significantly reduce the efficiency of programmed ribosome frameshift when the mRNA of HIV-1 translates a Gag-Pol fusion protein, so that the translation efficiency of the Pol protein is greatly reduced, thereby causing the ratio imbalance of Gag and Pol in cells, causing the virus not to be effectively packaged, and finally causing the sharp reduction of the yield of the virus, and having a good anti-HIV effect.

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)—or the like; each R1 independently represents a halogen atom or the like; each of R1a and R1b independently represents a hydrogen atom or the like, R2represents an alkyl group or a haloalkyl group, R3represents a hydrogen atom or an alkyl group; and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof; and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

This application relates to the field of biomedicine and discloses the use of EN219 in the preparation of drugs for preventing and treating AIDS. This application has confirmed that EN219 can promote the functions of innate immune cells, break through the immune escape strategy of HIV, and can inhibit the replication of HIV in immune cells. To a certain extent, it overcomes the drawback of high compliance of traditional AIDS treatment drugs, discovers a new host drug target, and has a brand-new application prospect.

The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection. (Formula (I))

The invention aims to provide a traditional Chinese medicine composition for treating AIDS (Acquired Immune Deficiency Syndrome). The pharmaceutical composition is prepared by processing the following raw material medicines: astragalus membranaceus, codonopsis pilosula, radix scrophulariae, bran-fried rhizoma atractylodis macrocephalae, Chinese yam, pericarpium citri reticulatae, angelica sinensis, salvia miltiorrhiza, ligusticum wallichii, radix cyathulae, raw liquorice, scorched hawthorn fruit, scorched medicated leaven and scorched malt. Pharmacodynamic tests prove that the medicine can enhance the immune function of AIDS patients, delay the decline speed of CD4 + T cells, activate latent HIV viruses and reservoirs, slow down the disease progress, protect the liver function, relieve clinical symptoms and the like.

The invention discloses application of a traditional Chinese medicine composition in preparation of traditional Chinese medicines for adjuvant therapy of AIDS. The traditional Chinese medicine composition is mainly prepared from the following medicinal materials: radix bupleuri, celosia cristata, salvia miltiorrhiza, fructus lycii, liquorice, artemisia capillaris, snake slough, schisandra chinensis, cordyceps sinensis and pig bile powder. The traditional Chinese medicine for adjuvant therapy of AIDS has the effects of resisting HIV, soothing liver-qi stagnation and tonifying spleen and qi, and can be used for clearing away heat and toxic materials, resisting inflammation and viruses and adjuvant therapy of AIDS. The traditional Chinese medicine composition has the pharmacological effects of resisting viruses, resisting inflammation and the like, can effectively inhibit reverse transcription of viruses, and has a good treatment effect on HIV (human immunodeficiency virus) and HBV (hepatitis B virus) infection. In addition, main components of the traditional Chinese medicine composition come from the nature, so that the traditional Chinese medicine composition has the advantages of being natural and safe, and has good safety in clinical application.

The invention relates to the medical technical field of rehabilitation treatment of AIDS patients, in particular to a production device of supersaturated dissolved hydroxyl antiviral drinking water for AIDS patients. Rehabilitation of AIDS patients is a problem in the technical field of medical treatment in the world at present. The human immunodeficiency virus has the characteristic of extremely high variation speed and attacks the immune system of a human body. After an immune system is destroyed, a patient loses an immune protection effect on any bacteria and viruses, and other diseases threaten the body health of the patient all the time. Although a cocktail therapy is invented by medical experts abroad, the effect is still unsatisfactory when various antiviral drugs are mixed to treat AIDS (Acquired Immune Deficiency Syndrome). According to the production device of the supersaturated dissolved hydroxyl antiviral drinking water for the AIDS patients, the patients drink high-concentration hydroxyl water which can resist viruses and does not have any toxic or side effect on the bodies, the antiviral hydroxyl water is conveyed to all the parts of the bodies through a digestive system, viruses are efficiently killed without dead corners, and the human immunity is improved. Virus variation is blocked; and the virus is killed. A device for producing supersaturated dissolved hydroxyl antiviral drinking water for AIDS patients comprises a box body, a hydroxyl radical generator, a household drinking water magnetizing water purifier, a high-pressure air pump, a high-pressure shearing atomizing nozzle, a stainless steel reaction tank, a vacuum pressure gauge, a high-pressure atomizing nozzle and an electromagnetic valve. And the sterilization and disinfection hydroxyl water production device is composed of one-way valves. After a patient drinks the hydroxyl water, sterilization and disinfection factors are conveyed to all parts of the human body through a digestive system, viruses invading the interior of the human body are killed, and the rehabilitation treatment effect is achieved.

The application discloses application of a PHD3 inhibitor in prevention and treatment of AIDS. Through immunological, biochemical and other multidisciplinary research means, the application analyzes the mechanism that a viral antisense protein ASP inhibits production of type I IFN to realize immune escape and establish latent infection in an HIV-1 infection process. Mechanically, after being expressed into a protein in a cell in the body, the ASP needs to undergo post-translational modification to exert its inhibiting effect, and after hydroxylation modification of a 47-position proline, the ASP can help to realize the ability of inhibiting the body immune response, and the post-translational modification depends on a host proline hydroxylase 3 (PHD3) to realize. Based on the mechanism-based research, it is found that a PHD3 inhibitor Molidustat offsets the hydroxylation of the ASP by PHD3, thereby blocking the immune evasion of HIV-1 and antagonizing infection, and showing a good development prospect of an AIDS treatment and prevention drug.

The present disclosure provides a composition for treating a viral infection. In one aspect, the present disclosure provides a composition for treating a viral infection in a subject, the composition containing a nucleic acid construct containing, in an operable manner, a nucleic acid sequence encoding an antigen protein contained in a virus belonging to the genus Lentivirus or a part thereof and a nucleic acid sequence encoding Ag85B protein. In one embodiment, the composition of the present disclosure is administered after the viral infection.

This invention belongs to the field of pharmaceutical technology, specifically relating to a pyrimidine cyclic compound containing deuterated methyl groups, its preparation method, and its uses. The compound structure of this invention is shown in general formula I, and also includes its pharmaceutical salt, hydrate, and solvate, its polycrystalline or cocrystalline forms, and its precursors and derivatives with similar biological functions. This compound or its composition can be used to prepare drugs for the prevention or treatment of AIDS and related diseases. In vitro cellular level anti-HIV-1 activity experiments show that this type of small molecule has strong anti-HIV-1 biological activity, significantly inhibiting viral replication in HIV-1-infected MT-4 cells, and exhibiting low cytotoxicity.

This invention belongs to the field of pharmaceutical technology, specifically relating to heteroarylpyrimidine derivatives containing a pyridine-benzene ring structure, their preparation methods, and uses. The compounds of this invention are heteroarylpyrimidine derivatives containing a pyridine-benzene ring structure, and also include their pharmaceutical salts, hydrates, and solvates, as well as their polycrystalline or cocrystalline forms, and their precursors and derivatives with similar biological functions. These compounds or combinations thereof can be used to prepare drugs for the prevention or treatment of AIDS and related diseases. In vitro cellular level anti-HIV-1 activity experiments show that these small molecules possess strong anti-HIV-1 biological activity, significantly inhibiting viral replication in HIV-1-infected MT-4 cells, and exhibiting low cytotoxicity.

The use of EN219 in the preparation of a drug for preventing and treating AIDS. The present application confirms that EN219 can promote the function of innate immune cells, disrupt the immune escape strategy of HIV, and inhibit the replication of HIV in immune cells. The present application overcomes, to a certain extent, the drawback of high medication adherence required by traditional AIDS treatment drugs, discovers a new host drug target, and has brand-new application prospects.

The invention belongs to the technical field of medicines, and particularly relates to an HIV-1 (human immunodeficiency virus-1) non-nucleoside reverse transcriptase inhibitor as well as a preparation method and application thereof. The HIV-1 non-nucleoside reverse transcriptase inhibitor is a piperidine-hydroxymethyl-diarylpyrimidine derivative, has two structural formulae, and also comprises a pharmaceutical salt, a hydrate, a solvate, a polycrystalline or a eutectic of the HIV-1 non-nucleoside reverse transcriptase inhibitor. The compound or the composition thereof can be used for preparing medicines for preventing or treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, remarkably inhibits virus replication in MT-4 cells infected by an HIV-1 virus, and has relatively low cytotoxicity.

Compositions and methods for inhibiting HIV protease are disclosed. The compositions include an extract from Cassia acutifolia stems, or a fraction thereof, alone or in a pharmaceutically acceptable carrier. The extracts can be obtained by subjecting Cassia acutifolia pulverized stems to methanol / dichloromethane (1:1) extraction. In a first extraction stage, Cassia acutifolia pulverized stems are macerated in a mixture of methanol / dichloromethane. In a second stage methanol is added to the remaining marc vortex and extracted for a suitable time period at room temperature. The extract from the first and second stages are combined. The extracts can be further processed for formulation into a suitable pharmaceutical form.

The invention belongs to the technical field of medicines, and particularly relates to a dihydropyridino [3, 4-D] pyrimidine compound as well as a preparation method and application thereof. The dihydropyrido [3, 4-D] pyrimidine compound disclosed by the invention is an HIV-1 (human immunodeficiency virus-1) non-nucleoside reverse transcriptase inhibitor. The invention also discloses pharmaceutical salts, hydrates, solvates, polycrystals or co-crystals of the compounds, precursors and derivatives with the same biological functions of the compounds, a preparation method of the compounds and application of a composition containing one or more of the compounds in related medicines for treating AIDS and the like. An in-vitro cellular level anti-HIV-1 activity experiment result shows that the small molecule compound has relatively strong anti-HIV-1 activity, can effectively inhibit the replication of HIV-1 viruses in MT-4 cells infected by the HIV-1 viruses, and has relatively low cytotoxicity.

The application aims to provide a traditional Chinese medicine composition for treating AIDS.The traditional Chinese medicine composition is prepared from the following raw medicines: Huangqi, Dangshen, Xuanshen, white atractylodes processed with wheat bran, Shanyao, Chenpi, Dangui, Danshen, Chuanqiong, Chuan Niuxi, Shenganshi, Jiaoshanzha, Jiaoshenqu and Jiaoma. The pharmacodynamic test proves that the medicine can enhance the immune function of AIDS patients, delay the decline speed of CD4+ T cells, activate latent HIV virus and reservoir, slow down the disease progress, protect the liver function and relieve the clinical symptoms.

The present disclosure relates generally to compounds of Formula I represented below: [Image disponible dans le document PDF, Image available in the PDF document] The present disclosre also relates to pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.

A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.

The purpose of the present invention is to provide a medicine useful for treating HIV infection by using compounds having different mechanisms in combination with kick and kill therapy. A medicine characterized by being a combination of (A) a polynucleotide or polypeptide that induces an anti-HIV Tat antibody that inhibits the activity of HIV Tat protein secreted from HIV-infected cells, and (B) a pattern recognition receptor agonist that induces type I IFN, is useful for the treatment, etc., of HIV infection.